How long would you continue trastuzumab and pertuzumab in a patient with ER+ HER2+ breast cancer with initially osseous involvement treated with ACT-HP and is now in CR by PET for >2 years?  

Medical Oncologist
Medical Oncologist at Arizona Hem/Onc
I would consider taking advantage of NGS and circu...
Medical Oncologist
A very interesting point! My only concern is that ...
Medical Oncologist at NYU Winthrop Hospital
Circulating tumor DNA not endorsed by NCCN in brea...
Sign in or Register to read more